HRS9531 Guide

HRS9531 is Hengrui Medicine\'s long-acting GLP-1/GIP co-agonist peptide. Like tirzepatide, it activates both the glucagon-like peptide-1 receptor and the glucose-dependent insulinotropic polypeptide receptor — but with a different amino acid backbone designed to optimize the receptor activation ratio. The FRUITION Phase 3 program enrolled patients with obesity in China, producing headline weight loss results that rival or exceed tirzepatide. HRS9531 represents the competitive next wave from Chinese pharmaceutical innovation challenging Western GLP-1 leaders in the multi-billion dollar obesity market.

Starting dose — GI acclimatization phase

First escalation — meaningful efficacy begins

Standard maintenance dose in trials

Max dose — 24.8% weight loss achieved here

Note: Final approved dosing may vary. Follow your prescriber's guidance. Use Shotlee to log each weekly dose and monitor your progress.